Aligos Therapeutics (NASDAQ:ALGS) Price Target Increased to $7.00 by Analysts at Piper Sandler

Aligos Therapeutics (NASDAQ:ALGSGet Rating) had its price objective increased by Piper Sandler from $3.00 to $7.00 in a research report sent to investors on Monday, The Fly reports.

Other equities research analysts also recently issued reports about the stock. SVB Leerink dropped their price target on shares of Aligos Therapeutics from $3.00 to $2.00 and set a market perform rating for the company in a research report on Thursday, November 3rd. Jefferies Financial Group upgraded shares of Aligos Therapeutics from a hold rating to a buy rating and lifted their price target for the company from $2.50 to $3.00 in a research report on Friday, January 6th.

Aligos Therapeutics Stock Up 13.9 %

Shares of ALGS stock opened at $1.64 on Monday. The firm has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.18. The company has a market capitalization of $70.22 million, a PE ratio of -0.62 and a beta of 1.80. Aligos Therapeutics has a 12-month low of $0.84 and a 12-month high of $3.41.

Aligos Therapeutics (NASDAQ:ALGSGet Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.13. The firm had revenue of $4.11 million during the quarter. Aligos Therapeutics had a negative net margin of 1,041.95% and a negative return on equity of 75.01%. As a group, research analysts expect that Aligos Therapeutics will post -2.21 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Aligos Therapeutics by 3.8% during the first quarter. State Street Corp now owns 404,756 shares of the company’s stock worth $870,000 after buying an additional 14,719 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Aligos Therapeutics by 1.7% during the first quarter. Bank of America Corp DE now owns 1,184,258 shares of the company’s stock valued at $2,546,000 after purchasing an additional 19,958 shares during the period. Wedmont Private Capital acquired a new position in shares of Aligos Therapeutics during the second quarter valued at about $25,000. PDT Partners LLC bought a new stake in shares of Aligos Therapeutics during the first quarter worth about $57,000. Finally, Prelude Capital Management LLC purchased a new stake in Aligos Therapeutics in the 1st quarter valued at about $58,000. 64.53% of the stock is owned by institutional investors.

About Aligos Therapeutics

(Get Rating)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.

Featured Stories

The Fly logo

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.